Are you or someone you know taking GLP-1 drugs like Ozempic or Wegovy? These medications, wildly popular for weight loss and diabetes treatment, are now at the center of a growing controversy. But here's where it gets controversial: patients in Marion County, Indiana, are filing lawsuits, alleging that pharmaceutical companies downplayed the severity of potential side effects.
These drugs, including names like Ozempic, Wegovy, Zepbound, and Mounjaro, have become incredibly common. WRTV Investigates is taking a deep dive into the benefits and the potential drawbacks of these medications.
On the one hand, GLP-1 drugs offer significant benefits. But it's essential to be aware of the potential downsides. Common side effects include muscle loss, nausea, vomiting, diarrhea, and constipation. Sue Seyfert, an Indiana resident, considers herself fortunate, as she has not experienced any side effects. However, it's not the same for everyone.
Andy Schmelz, an associate professor of pharmacy practice at Butler University, notes that gastrointestinal issues are common. "Most patients will experience some kind of stomach-related side effect like nausea, vomiting, diarrhea, constipation," he explains. He also points out the black box warning associated with GLP-1 drugs regarding thyroid tumors, urging caution for those with a family or personal history of thyroid cancer.
Dozens of lawsuits have been filed in Marion County against Eli Lilly and Novo Nordisk, the makers of these drugs. The core of these lawsuits? The claim that the companies understated the risks associated with these medications, specifically conditions like gastroparesis, where the stomach struggles to empty itself.
One lawsuit, filed by Terry Smith, alleges he suffered severe gastroparesis, debilitating vomiting, and abdominal pain after using Ozempic, Trulicity, and Victoza. He is seeking damages from Eli Lilly and Novo Nordisk. Smith's lawsuit and others suggest that instead of warning consumers about muscle loss, "Lilly has instead invested in developing combination drugs to combat the muscle loss." These lawsuits are still pending.
When approached for comment, Eli Lilly stated their commitment to patient safety, highlighting the robust warnings included in their medicine labels. Novo Nordisk emphasized the extensive research supporting the safety and efficacy of their semaglutide products. They believe the lawsuits lack merit and intend to defend against the claims.
The financial stakes are high. Eli Lilly reported a 54% increase in revenue in Q3 2025, reaching $17.60 billion, driven by Mounjaro and Zepbound. Novo Nordisk's semaglutide sales, including Wegovy and Ozempic, brought in over 51 billion Danish kroner, or about $7.9 billion. Novo Nordisk also reported a 12% increase in sales in the first nine months of 2025.
U.S. regulators recently approved a pill version of Wegovy, further expanding the market.
This raises a critical question: Are the potential side effects being adequately communicated to patients? What are your thoughts on this rapidly evolving situation? Share your opinions in the comments below.
Disclaimer: This information is based on reports from WRTV and is for informational purposes only. Consult with a healthcare professional for medical advice.
